Skip to content
HowShorted

INOVIO PHARMACEUTICALS, INC. short interest in 2019

In 2019, INOVIO PHARMACEUTICALS, INC.'s disclosed short interest ran from 6.75% of shares outstanding on 15 Jan 2019 to 10.41% on 31 Dec 2019, a change of +3.66 percentage points. The year's high was 14.65% on 30 Apr 2019 and its low 6.75% on 15 Jan 2019, averaging 11.43% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.02 days on 15 Oct 2019. Full history: INOVIO PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for INOVIO PHARMACEUTICALS, INC. in 2019

2019 in figures

Start of year
6.75% (15 Jan 2019)
End of year
10.41% (31 Dec 2019)
Change
+3.66 pp
High
14.65% (30 Apr 2019)
Low
6.75% (15 Jan 2019)
Average
11.43%
Highest days to cover
25.02 (15 Oct 2019)
SEC filings marked
5

Every report in 2019

INOVIO PHARMACEUTICALS, INC. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20196.75%8.41
31 Jan 20196.96%8.09
15 Feb 20197.35%4.21results (8-K)
28 Feb 20199.85%5.08
15 Mar 201912.39%7.0410-K filed
29 Mar 201913.81%10.86
15 Apr 201914.35%12.36
30 Apr 201914.65%15.64
15 May 201914.59%16.2210-Q filed
31 May 201914.06%12.52
14 Jun 201914.10%11.74
28 Jun 201912.02%6.52
15 Jul 201911.39%21.21
31 Jul 201911.20%15.80
15 Aug 201911.13%16.9110-Q filed
30 Aug 201911.07%21.98
13 Sep 201911.23%18.22
30 Sep 201911.78%22.43
15 Oct 201911.82%25.02
31 Oct 201911.20%19.45
15 Nov 201911.02%10.3510-Q filed
29 Nov 201910.69%12.31
13 Dec 201910.57%15.08
31 Dec 201910.41%6.45

See also: INOVIO PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.